Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C61084
http://purl.obolibrary.org/obo/NCIT_C61084
|
|---|---|
| Preferred Name | Siltuximab |
| Definitions |
A chimeric, human-murine, monoclonal antibody targeting the pro-inflammatory cytokine interleukin 6 (IL-6), with antitumor and anti-inflammatory activities. Upon intravenous administration of siltuximab, this agent targets and binds to IL-6. This inhibits the binding of IL-6 to the IL-6 receptor (IL-6R), which results in the blockade of the IL-6/IL-6R-mediated signal transduction pathway. This inhibits cancer cell growth in tumors overexpressing IL-6.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A chimeric, human-murine, monoclonal antibody targeting the pro-inflammatory cytokine interleukin 6 (IL-6), with antitumor and anti-inflammatory activities. Upon intravenous administration of siltuximab, this agent targets and binds to IL-6. This inhibits the binding of IL-6 to the IL-6 receptor (IL-6R), which results in the blockade of the IL-6/IL-6R-mediated signal transduction pathway. This inhibits cancer cell growth in tumors overexpressing IL-6. |
|---|---|
| label | Siltuximab
|
| prefLabel | Siltuximab
|
| Legacy Concept Name | Anti-IL-6_Chimeric_Monoclonal_Antibody
|
| in_subset |
See more
See less
|
| Preferred_Name | Siltuximab
|
| Is_Value_For_GDC_Property | |
| Display_Name | Siltuximab
|
| Maps_To | Siltuximab
|
| PDQ_Open_Trial_Search_ID | 475765
|
| Has_Target | |
| FDA_UNII_Code | T4H8FMA7IM
|
| prefixIRI | NCIT:C61084
|
| Accepted_Therapeutic_Use_For | multicentric Castleman's disease (MCD)
|
| NCI_Drug_Dictionary_ID | 475765
|
| Contributing_Source |
CTRP
FDA
|
| subClassOf | |
| code | C61084
|
| type | |
| ALT_DEFINITION | A chimeric (made from human and mouse proteins) monoclonal antibody being studied in the treatment of advanced kidney cancer and other types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Anti-IL-6 chimeric monoclonal antibody works by blocking inflammation and tumor growth.
|
| PDQ_Closed_Trial_Search_ID | 475765
|
| Semantic_Type |
Amino Acid, Peptide, or Protein
Pharmacologic Substance
|
| CAS_Registry | 541502-14-1
|
| NCI_META_CUI | CL776663
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |